Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
Spain
Hospital Universitari Vall d'Hebron, Barcelona Hospital Universitario Reina Sofía, Córdoba Hospital General Universitario Gregorio Marañon, Madrid Hospital Universitario Ramón y Cajal, Madrid Hospital Universitario La Paz, Madrid Hospital Universitario Virgen del Rocío, Seville United Kingdom
Bristol Royal Infirmary, Bristol Royal Infirmary of Edinburgh, Edinburgh Glasgow Royal Infirmary, Glasgow Royal Liverpool University Hospital, Liverpool King's College Hospital, London St George's Hospital, London St Mary's Hospital, London Nottingham University Hospital, Nottingham